140 related articles for article (PubMed ID: 35677163)
1. Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment.
Takeshita T; Tokumaru Y; Oshi M; Wu R; Patel A; Tian W; Hatanaka Y; Hatanaka KC; Yan L; Takabe K
Front Oncol; 2022; 12():865024. PubMed ID: 35677163
[TBL] [Abstract][Full Text] [Related]
2. KRAS signaling enriched triple negative breast cancer is associated with favorable tumor immune microenvironment and better survival.
Tokumaru Y; Oshi M; Katsuta E; Yan L; Satyananda V; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Am J Cancer Res; 2020; 10(3):897-907. PubMed ID: 32266098
[TBL] [Abstract][Full Text] [Related]
3. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral lymphatic endothelial cell infiltration reflecting lymphangiogenesis is counterbalanced by immune responses and better cancer biology in the breast cancer tumor microenvironment.
Wu R; Sarkar J; Tokumaru Y; Takabe Y; Oshi M; Asaoka M; Yan L; Ishikawa T; Takabe K
Am J Cancer Res; 2022; 12(2):504-520. PubMed ID: 35261783
[TBL] [Abstract][Full Text] [Related]
5. High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer.
Oshi M; Tokumaru Y; Benesch MG; Sugito N; Wu R; Yan L; Yamada A; Chishima T; Ishikawa T; Endo I; Takabe K
Am J Cancer Res; 2022; 12(10):4840-4852. PubMed ID: 36381329
[TBL] [Abstract][Full Text] [Related]
6. Inflammation Is Associated with Worse Outcome in the Whole Cohort but with Better Outcome in Triple-Negative Subtype of Breast Cancer Patients.
Oshi M; Newman S; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
J Immunol Res; 2020; 2020():5618786. PubMed ID: 33457427
[TBL] [Abstract][Full Text] [Related]
7. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
[TBL] [Abstract][Full Text] [Related]
8. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
[No Abstract] [Full Text] [Related]
9. Development of a Machine Learning-Based Prognostic Model for Hormone Receptor-Positive Breast Cancer Using Nine-Gene Expression Signature.
Takeshita T; Iwase H; Wu R; Ziazadeh D; Yan L; Takabe K
World J Oncol; 2023 Oct; 14(5):406-422. PubMed ID: 37869243
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Immunofunctional Phenotyping on the Malfunction of the Cancer Immunity Cycle in Breast Cancer.
Takeshita T; Torigoe T; Yan L; Huang JL; Yamashita H; Takabe K
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396390
[TBL] [Abstract][Full Text] [Related]
11. Increased apoptosis is associated with robust immune cell infiltration and cytolytic activity in breast cancer.
Murthy V; Oshi M; Tokumaru Y; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3674-3687. PubMed ID: 34354867
[TBL] [Abstract][Full Text] [Related]
12. The IL1β-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs).
Lappano R; Talia M; Cirillo F; Rigiracciolo DC; Scordamaglia D; Guzzi R; Miglietta AM; De Francesco EM; Belfiore A; Sims AH; Maggiolini M
J Exp Clin Cancer Res; 2020 Aug; 39(1):153. PubMed ID: 32778144
[TBL] [Abstract][Full Text] [Related]
13. MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer.
Schulze A; Oshi M; Endo I; Takabe K
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143224
[No Abstract] [Full Text] [Related]
14. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
[TBL] [Abstract][Full Text] [Related]
15. Systematic Chromatin Accessibility Analysis Based on Different Immunological Subtypes of Clear Cell Renal Cell Carcinoma.
Zhang S; Zheng W; Jiang D; Xiong H; Liao G; Yang X; Ma H; Li J; Qiu M; Li B; Sun C; Zhao J; Wang L; Pang J
Front Oncol; 2021; 11():575425. PubMed ID: 33937014
[TBL] [Abstract][Full Text] [Related]
16. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
17. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.
Takeshita T; Yan L; Asaoka M; Rashid O; Takabe K
Sci Rep; 2019 Nov; 9(1):16942. PubMed ID: 31729458
[TBL] [Abstract][Full Text] [Related]
18. Octogenarians' Breast Cancer Is Associated with an Unfavorable Tumor Immune Microenvironment and Worse Disease-Free Survival.
Okano M; Oshi M; Mukhopadhyay S; Qi Q; Yan L; Endo I; Ohtake T; Takabe K
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34208219
[TBL] [Abstract][Full Text] [Related]
19. Immunological Differences Between Immune-Rich Estrogen Receptor-Positive and Immune-Rich Triple-Negative Breast Cancers.
O'Meara T; Marczyk M; Qing T; Yaghoobi V; Blenman K; Cole K; Pelekanou V; Rimm DL; Pusztai L
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923897
[TBL] [Abstract][Full Text] [Related]
20. The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.
Talia M; De Francesco EM; Rigiracciolo DC; Muoio MG; Muglia L; Belfiore A; Maggiolini M; Sims AH; Lappano R
Cells; 2020 Mar; 9(3):. PubMed ID: 32143514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
